AR092532A1 - Etanercept correctamente plegado de alta pureza y excelente rendimiento - Google Patents
Etanercept correctamente plegado de alta pureza y excelente rendimientoInfo
- Publication number
- AR092532A1 AR092532A1 ARP130103250A ARP130103250A AR092532A1 AR 092532 A1 AR092532 A1 AR 092532A1 AR P130103250 A ARP130103250 A AR P130103250A AR P130103250 A ARP130103250 A AR P130103250A AR 092532 A1 AR092532 A1 AR 092532A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- folded
- correctly folded
- etanercept
- mixed mode
- Prior art date
Links
- 108010008165 Etanercept Proteins 0.000 title abstract 6
- 229960000403 etanercept Drugs 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 abstract 11
- 102000004169 proteins and genes Human genes 0.000 abstract 11
- 238000000034 method Methods 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 4
- 238000012434 mixed-mode chromatography Methods 0.000 abstract 3
- 238000002360 preparation method Methods 0.000 abstract 3
- 239000012539 chromatography resin Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 238000005342 ion exchange Methods 0.000 abstract 1
- 239000011347 resin Substances 0.000 abstract 1
- 229920005989 resin Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Método de cromatografía de modo mixto para separar las conformaciones correctamente plegadas de las incorrectamente plegadas de una proteína dada. El método es muy eficaz en la separación de etanercept correctamente plegado del etanercept incorrectamente plegado y de agregados con rendimientos comercialmente atractivos que permiten obtener preparaciones de etanercept de una muy alta pureza en términos de etanercept correctamente plegado versus etanercept incorrectamente plegado. La solicitud está dirigida además a preparaciones de proteínas y formulaciones que comprenden proteínas correctamente plegadas obtenidas usando los métodos de la presente, y métodos de tratamiento que emplean las preparaciones de gran pureza obtenidas del método de modo mixto. Reivindicación 1: Un método de cromatografía de modo mixto para separar una proteína correctamente plegada de una proteína incorrectamente plegada, que comprende los pasos de: (a) unir una primera mezcla de proteínas que comprende ambas conformaciones correctamente plegada e incorrectamente plegada de una proteína dada con una resina de cromatografía de modo mixto que tiene porciones de intercambio iónico y porciones hidrofóbicas; (b) eluir la proteína correctamente plegada de la resina de modo mixto para obtener una segunda mezcla de proteínas que Comprende una mayor proporción de proteína correctamente plegada que la primera mezcla de proteínas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699552P | 2012-09-11 | 2012-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092532A1 true AR092532A1 (es) | 2015-04-22 |
Family
ID=50233493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103250A AR092532A1 (es) | 2012-09-11 | 2013-09-11 | Etanercept correctamente plegado de alta pureza y excelente rendimiento |
Country Status (33)
| Country | Link |
|---|---|
| US (6) | US20140072560A1 (es) |
| EP (1) | EP2895188B1 (es) |
| JP (3) | JP2015533797A (es) |
| KR (2) | KR102133699B1 (es) |
| CN (2) | CN104902914B (es) |
| AR (1) | AR092532A1 (es) |
| AU (2) | AU2013315750B9 (es) |
| BR (1) | BR112015005161A2 (es) |
| CA (1) | CA2882551A1 (es) |
| CL (1) | CL2015000572A1 (es) |
| CO (1) | CO7400876A2 (es) |
| CY (1) | CY1120062T1 (es) |
| DK (1) | DK2895188T3 (es) |
| DO (1) | DOP2015000055A (es) |
| EA (1) | EA031324B1 (es) |
| EC (1) | ECSP15014138A (es) |
| ES (1) | ES2657377T3 (es) |
| HR (1) | HRP20180182T1 (es) |
| HU (1) | HUE036524T2 (es) |
| IL (2) | IL237311B (es) |
| IN (1) | IN2015KN00452A (es) |
| LT (1) | LT2895188T (es) |
| MX (2) | MX360044B (es) |
| NO (1) | NO2972131T3 (es) |
| PE (2) | PE20200607A1 (es) |
| PL (1) | PL2895188T3 (es) |
| PT (1) | PT2895188T (es) |
| RS (1) | RS57013B1 (es) |
| SG (1) | SG11201501460RA (es) |
| SI (1) | SI2895188T1 (es) |
| SM (1) | SMT201800163T1 (es) |
| TW (2) | TWI609877B (es) |
| WO (1) | WO2014043103A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | SELF-BUFFING PROTEIN FORMULATIONS |
| US10485869B2 (en) | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
| TWI595883B (zh) | 2011-10-18 | 2017-08-21 | 柯赫勒斯生物科學有限公司 | 用木糖醇穩定化之依那西普調配物 |
| BR112015005161A2 (pt) * | 2012-09-11 | 2017-07-04 | Coherus Biosciences Inc | etanercepte corretamente dobrado em alta pureza e excelente rendimento |
| US10556942B2 (en) | 2014-06-13 | 2020-02-11 | Lupin Limited | Process for the purification of TNFR:Fc fusion protein |
| EP2975050B1 (en) * | 2014-07-18 | 2019-05-29 | Sandoz Ag | Quantification of misfolded TNFR2:Fc |
| US10988527B2 (en) | 2014-12-31 | 2021-04-27 | Lg Chem, Ltd. | Method for preparing TNFR-Fc fusion protein containing target content of impurities |
| KR20170138426A (ko) | 2015-03-13 | 2017-12-15 | 삼성바이오에피스 주식회사 | 항-tnf-알파 폴리펩티드 조성물 및 그 용도 |
| MX2018005831A (es) * | 2015-11-18 | 2018-08-01 | Merck Patent Gmbh | Gradientes de ph-sal opuestos para separaciones de proteina mejoradas. |
| KR20180083409A (ko) * | 2015-11-18 | 2018-07-20 | 메르크 파텐트 게엠베하 | 이온 교환 크로마토그래피에서의 개선된 단백질 분리 |
| PL3472177T3 (pl) * | 2016-06-17 | 2024-11-25 | F. Hoffmann-La Roche Ag | Oczyszczanie przeciwciał wieloswoistych |
| KR102446838B1 (ko) * | 2016-10-21 | 2022-09-26 | 암젠 인크 | 약학적 제형 및 그의 제조 방법 |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| JP7655610B2 (ja) * | 2017-03-24 | 2025-04-02 | カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ | 組換え抗体断片の精製方法 |
| CA3042126A1 (en) | 2018-05-03 | 2019-11-03 | Michael A. Portman | Methods of treating kawasaki disease |
| CN112876567A (zh) * | 2019-11-29 | 2021-06-01 | 广东菲鹏制药股份有限公司 | Fc融合蛋白及其纯化方法 |
| US20230167153A1 (en) | 2020-05-01 | 2023-06-01 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| JP2024510480A (ja) * | 2021-03-16 | 2024-03-07 | カシーヴ バイオサイエンシズ,リミテッド・ライアビリティ・カンパニー | 融合タンパク質の新規製剤 |
| WO2022234412A1 (en) * | 2021-05-03 | 2022-11-10 | Lupin Limited | A process for purification of fc-fusion proteins |
| AU2022369694B2 (en) * | 2021-10-19 | 2025-10-09 | Alteogen, Inc | Method for purifying fusion protein having igg fc domain |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
| ATE309376T1 (de) | 1990-06-28 | 2005-11-15 | Hoechst Ag | Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung |
| CA2123593C (en) | 1992-09-15 | 2000-03-14 | Craig A. Smith | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US7294481B1 (en) | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US20010021380A1 (en) | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| CA2366785C (en) | 1999-04-19 | 2012-02-07 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| WO2001058473A1 (en) | 2000-02-10 | 2001-08-16 | Wyeth | Method of treating or inhibiting cellular injury or cell death |
| ES2477996T3 (es) | 2000-08-11 | 2014-07-18 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen un anticuerpo |
| EE200300408A (et) | 2001-02-23 | 2003-12-15 | Immunex Corporation | Aktiivsete valkude saagise suurendamine |
| PT1478394E (pt) * | 2002-02-27 | 2008-10-08 | Immunex Corp | Composição estabilizada compreendendo tnfr - fc e arginina |
| WO2004017955A1 (en) * | 2002-08-22 | 2004-03-04 | Vasopharm Biotech Gmbh | L-arginine containing pharmaceutical composition |
| US20040115263A1 (en) | 2002-08-26 | 2004-06-17 | Robertson David W. | Use of bupropion for treating restless legs syndrome |
| US8937045B2 (en) | 2003-02-28 | 2015-01-20 | Ares Trading S.A. | Liquid formulations of tumor necrosis factor-binding proteins |
| WO2004082715A1 (ja) | 2003-03-20 | 2004-09-30 | Eisai Co., Ltd. | 炎症性腸疾患治療剤としての併用医薬 |
| NZ545221A (en) | 2003-08-01 | 2009-09-25 | Amgen Inc | Crystalline tumor necrosis factor receptor 2 polypeptides |
| RS20110578A3 (en) | 2003-10-14 | 2016-02-29 | F. Hoffmann-La Roche Ltd | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS |
| US7750129B2 (en) * | 2004-02-27 | 2010-07-06 | Ge Healthcare Bio-Sciences Ab | Process for the purification of antibodies |
| WO2005082377A1 (ja) | 2004-03-01 | 2005-09-09 | Ajinomoto Co., Inc. | 抗ヒトTNF-α抗体活性低下抑制剤 |
| CN1930281A (zh) | 2004-03-05 | 2007-03-14 | 帝斯曼知识产权资产管理有限公司 | 用于通过连续灌注和交互切向流来培养细胞的方法 |
| US20070196364A1 (en) | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
| TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| CA2607697C (en) | 2005-05-10 | 2015-01-06 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
| JP5068167B2 (ja) | 2005-06-10 | 2012-11-07 | 中外製薬株式会社 | メグルミンを含有するタンパク質製剤の安定化剤、およびその利用 |
| CA2634547C (en) | 2005-12-20 | 2016-10-11 | Bristol-Myers Squibb Company | Stable ctla4 formulation for subcutaneous administration |
| JP5405122B2 (ja) | 2005-12-21 | 2014-02-05 | ワイス・エルエルシー | 低粘度のタンパク質製剤およびその用途 |
| KR20080098504A (ko) | 2006-02-03 | 2008-11-10 | 메디뮨 엘엘씨 | 단백질 제제 |
| BRPI0709598A8 (pt) | 2006-03-17 | 2019-01-08 | Biogen Idec Inc | composições de polipeptídeos estabilizados |
| JP2009534390A (ja) | 2006-04-21 | 2009-09-24 | アムジェン インコーポレイテッド | 生物医薬品製剤のための緩衝剤 |
| EP2081553B1 (en) | 2006-10-06 | 2020-08-12 | Amgen Inc. | Stable antibody formulations |
| WO2008051363A2 (en) | 2006-10-20 | 2008-05-02 | Amgen Inc. | Stable polypeptide formulations |
| JP5401319B2 (ja) | 2006-11-03 | 2014-01-29 | ワイス・エルエルシー | 細胞培養における解糖阻害物質 |
| EP2129401B8 (en) | 2006-12-21 | 2020-01-15 | Amgen Inc. | Stable buffered formulations containing polypeptides |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| KR20090127326A (ko) | 2007-03-02 | 2009-12-10 | 와이어쓰 | 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도 |
| EP2014760A1 (en) | 2007-06-13 | 2009-01-14 | CMC Biopharmaceuticals A/S | A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process |
| BRPI0814252B8 (pt) | 2007-06-14 | 2021-05-25 | Biogen Idec Inc | composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia |
| CA2707483A1 (en) | 2007-11-30 | 2009-06-11 | Wolfgang Fraunhofer | Protein formulations and methods of making same |
| AU2009222115A1 (en) | 2008-02-29 | 2009-09-11 | Biogen Idec Ma Inc. | Purified immunoglobulin fusion proteins and methods of their purification |
| JP5677943B2 (ja) * | 2008-06-05 | 2015-02-25 | アフィボディ・アーベーAffibody Ab | ポリペプチド |
| WO2011015926A1 (en) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein |
| JP5791602B2 (ja) | 2009-08-07 | 2015-10-07 | イー・エム・デイー・ミリポア・コーポレイシヨン | 試料中の1つ以上の不純物から標的タンパク質を精製するための方法 |
| KR20180010324A (ko) | 2009-08-11 | 2018-01-30 | 제넨테크, 인크. | 글루타민-비함유 세포 배양 배지에서의 단백질의 생성 |
| EP2490780A4 (en) * | 2009-10-20 | 2014-04-09 | Merck Sharp & Dohme | USE OF A MIXED MODE CHROMATOGRAPHY FOR THE DETECTION AND PURIFICATION OF BASIC ANTIBODY PRODUCTS |
| WO2011079308A2 (en) | 2009-12-23 | 2011-06-30 | Emergent Product Development Seattle, Llc | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
| JP6347949B2 (ja) | 2010-04-26 | 2018-06-27 | ノバルティス アーゲー | 改良型細胞培養培地 |
| RU2600847C2 (ru) * | 2010-05-10 | 2016-10-27 | Интас Биофармасьютикалс Лимитед | Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина |
| EP2598167B1 (en) | 2010-07-30 | 2015-04-01 | Arecor Limited | Stabilized aqueous antibody compositions |
| JP2013535981A (ja) | 2010-08-20 | 2013-09-19 | ワイス・エルエルシー | 成長因子不含適合細胞の細胞培養 |
| KR20130101034A (ko) | 2010-08-31 | 2013-09-12 | 프리슬랜드 브랜즈 비브이 | 진핵 세포를 위한 배양 배지 |
| CN103379949B (zh) * | 2010-10-11 | 2016-09-14 | 艾伯维巴哈马有限公司 | 蛋白纯化方法 |
| AU2012244764B2 (en) | 2011-04-20 | 2016-10-13 | Sandoz Ag | Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc |
| UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| AU2012279205B2 (en) | 2011-07-01 | 2017-08-31 | Biogen Ma Inc. | Arginine - free TNFR : Fc- fusion polypeptide compositions and methods of use |
| WO2013006479A2 (en) | 2011-07-01 | 2013-01-10 | Amgen Inc. | Mammalian cell culture |
| WO2013009526A1 (en) * | 2011-07-08 | 2013-01-17 | Merck Sharp & Dohme Corp. | Method for purifying fc-fusion protein |
| WO2013025079A1 (en) | 2011-08-17 | 2013-02-21 | Hanwha Chemical Corporation | Method for preparing active form of tnfr-fc fusion protein |
| US10485869B2 (en) * | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
| TWI595883B (zh) * | 2011-10-18 | 2017-08-21 | 柯赫勒斯生物科學有限公司 | 用木糖醇穩定化之依那西普調配物 |
| WO2014011672A1 (en) * | 2012-07-09 | 2014-01-16 | Coherus Biosciences, Inc. | Etanercept formulations exhibiting marked reduction in sub-visible particles |
| BR112015005161A2 (pt) * | 2012-09-11 | 2017-07-04 | Coherus Biosciences Inc | etanercepte corretamente dobrado em alta pureza e excelente rendimento |
| WO2016015163A1 (en) * | 2014-07-31 | 2016-02-04 | Mtt Innovation Incorporated | Numerical approaches for free-form lensing: area parameterization free-form lensing |
| US20160108634A1 (en) * | 2014-10-16 | 2016-04-21 | Ronald Uphold | Pool Cover Hanger Device |
-
2013
- 2013-09-10 BR BR112015005161A patent/BR112015005161A2/pt not_active Application Discontinuation
- 2013-09-10 CN CN201380058650.5A patent/CN104902914B/zh not_active Expired - Fee Related
- 2013-09-10 WO PCT/US2013/058994 patent/WO2014043103A1/en not_active Ceased
- 2013-09-10 HR HRP20180182TT patent/HRP20180182T1/hr unknown
- 2013-09-10 SI SI201330936T patent/SI2895188T1/en unknown
- 2013-09-10 ES ES13838016.7T patent/ES2657377T3/es active Active
- 2013-09-10 PE PE2019002512A patent/PE20200607A1/es unknown
- 2013-09-10 EP EP13838016.7A patent/EP2895188B1/en active Active
- 2013-09-10 SG SG11201501460RA patent/SG11201501460RA/en unknown
- 2013-09-10 EA EA201590542A patent/EA031324B1/ru unknown
- 2013-09-10 PT PT138380167T patent/PT2895188T/pt unknown
- 2013-09-10 AU AU2013315750A patent/AU2013315750B9/en not_active Ceased
- 2013-09-10 JP JP2015531311A patent/JP2015533797A/ja active Pending
- 2013-09-10 PL PL13838016T patent/PL2895188T3/pl unknown
- 2013-09-10 CN CN201811633164.2A patent/CN110051823A/zh active Pending
- 2013-09-10 PE PE2015000316A patent/PE20150996A1/es unknown
- 2013-09-10 MX MX2015003090A patent/MX360044B/es active IP Right Grant
- 2013-09-10 LT LTEP13838016.7T patent/LT2895188T/lt unknown
- 2013-09-10 SM SM20180163T patent/SMT201800163T1/it unknown
- 2013-09-10 CA CA2882551A patent/CA2882551A1/en active Pending
- 2013-09-10 IN IN452KON2015 patent/IN2015KN00452A/en unknown
- 2013-09-10 KR KR1020157009386A patent/KR102133699B1/ko not_active Expired - Fee Related
- 2013-09-10 KR KR1020207019733A patent/KR102250937B1/ko not_active Expired - Fee Related
- 2013-09-10 HU HUE13838016A patent/HUE036524T2/hu unknown
- 2013-09-10 DK DK13838016.7T patent/DK2895188T3/en active
- 2013-09-10 RS RS20180095A patent/RS57013B1/sr unknown
- 2013-09-11 US US14/023,736 patent/US20140072560A1/en not_active Abandoned
- 2013-09-11 AR ARP130103250A patent/AR092532A1/es not_active Application Discontinuation
- 2013-09-11 TW TW102132831A patent/TWI609877B/zh not_active IP Right Cessation
- 2013-09-11 TW TW106136921A patent/TWI716649B/zh not_active IP Right Cessation
-
2014
- 2014-03-13 NO NO14719160A patent/NO2972131T3/no unknown
-
2015
- 2015-02-19 IL IL237311A patent/IL237311B/en active IP Right Grant
- 2015-03-06 CL CL2015000572A patent/CL2015000572A1/es unknown
- 2015-03-10 DO DO2015000055A patent/DOP2015000055A/es unknown
- 2015-03-10 MX MX2018012749A patent/MX2018012749A/es unknown
- 2015-04-07 CO CO15076746A patent/CO7400876A2/es unknown
- 2015-04-10 EC ECIEPI201514138A patent/ECSP15014138A/es unknown
-
2017
- 2017-09-29 US US15/720,291 patent/US11001627B2/en not_active Expired - Fee Related
-
2018
- 2018-02-13 CY CY20181100172T patent/CY1120062T1/el unknown
- 2018-10-10 AU AU2018247244A patent/AU2018247244B2/en not_active Ceased
- 2018-10-11 JP JP2018192476A patent/JP6913066B2/ja not_active Expired - Fee Related
-
2019
- 2019-06-17 US US16/443,688 patent/US10947306B2/en not_active Expired - Fee Related
- 2019-06-17 US US16/443,514 patent/US10954293B2/en not_active Expired - Fee Related
- 2019-06-17 US US16/443,594 patent/US10954294B2/en not_active Expired - Fee Related
- 2019-06-17 US US16/443,721 patent/US10954295B2/en not_active Expired - Fee Related
- 2019-06-18 IL IL267452A patent/IL267452B/en active IP Right Grant
-
2021
- 2021-02-22 JP JP2021025939A patent/JP2021100929A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092532A1 (es) | Etanercept correctamente plegado de alta pureza y excelente rendimiento | |
| CY1125392T1 (el) | Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων | |
| CL2018000226A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
| WO2014141152A3 (en) | Low concentration antibody formulations | |
| CO2020001872A2 (es) | Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| DOP2018000259A (es) | Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral | |
| EA201991168A1 (ru) | Белок, связывающий простатический специфический мембранный антиген | |
| AR110645A1 (es) | Anticuerpos anti-hla-g y uso de los mismos | |
| CY1119576T1 (el) | Ν-ακυλ-(3-υποκατεστημενες)-(8-υποκατεστημενες)-5,6-διϋδρο-[1,2,4]τριαζολο[4,3-α]πυραζινες ως επιλεκτικοι ανταγωνιστες του υποδοχεα νκ-3, φαρμακευτικη συνθεση, μεθοδοι για χρηση σε διαμεσολαβουμενες απο τον υποδοχεα νκ-3 διαταραχες | |
| EA201892693A1 (ru) | Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3 | |
| PE20060816A1 (es) | Proceso para la concentracion de anticuerpos y productos terapeuticos de los mismos | |
| CO6491045A2 (es) | Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas | |
| AR090884A1 (es) | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc | |
| MY206284A (en) | Anti-cd63 antibodies, conjugates, and uses thereof | |
| EA201791350A9 (ru) | Радиофармацевтические комплексы | |
| MX387764B (es) | Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos. | |
| CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
| BR112018017174A2 (pt) | conjugados de aminoácido e peptídeo e processo de conjugação | |
| DOP2016000220A (es) | PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS. | |
| MX2018013685A (es) | Terapia de combinacion de cebadadura:refuerzo. | |
| CO2023004265A2 (es) | Métodos para reducir el contenido de proteínas de la célula huésped en procesos de purificación de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteínas de la célula huésped | |
| BR112012022292A2 (pt) | método para produção da proteína recombinante interferon solúvel sem desnaturação. | |
| HK1243329A1 (zh) | 谷氨酸草酰乙酸转氨酶1(got1)、其制剂、产生方法及用途 | |
| 김연숙 et al. | High Performance Liquid Chromatography Analysis of Human Salivary Protein Complexes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |